Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (19578)
All Articles published online
|
Publishing Process of This Article
|
Feb 26, 2015 (publication date) through Nov 20, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Cardiology
ISSN
1949-8462
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: Current status and perspectives in arrhythmia management. World J Cardiol 2015; 7(2): 76-85 [PMID: 25717355 DOI: 10.4330/wjc.v7.i2.76] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v7/i2/76.htm |
| Number | Citing Articles |
| 1 |
Hermann A.M. Mucke. Drug Repurposing Patent Applications January–March 2015. ASSAY and Drug Development Technologies 2015; 13(6): 332 doi: 10.1089/adt.2015.29017.patdrrr
|
| 2 |
Michael Sampson. Antiarrhythmic drugs part 2: rhythm-control drugs. British Journal of Cardiac Nursing 2019; 14(10): 1 doi: 10.12968/bjca.2019.0067
|
| 3 |
Alexandra Smith, Gregg Gerasimon. An electrocardiographic series of flecainide toxicity. Indian Pacing and Electrophysiology Journal 2019; 19(2): 75 doi: 10.1016/j.ipej.2018.11.012
|
| 4 |
Alexandra Njegic, Claire Wilson, Elizabeth J. Cartwright. Targeting Ca2 + Handling Proteins for the Treatment of Heart Failure and Arrhythmias. Frontiers in Physiology 2020; 11 doi: 10.3389/fphys.2020.01068
|
| 5 |
Sean P. Gaine, Hugh Calkins. Antiarrhythmic Drug Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy. Biomedicines 2023; 11(4): 1213 doi: 10.3390/biomedicines11041213
|
| 6 |
G. Andrei Dan. Resurrection of classical antiarrhythmic drugs. International Journal of Cardiology 2024; 412: 132300 doi: 10.1016/j.ijcard.2024.132300
|
| 7 |
Paola Spitalieri, Rosa V. Talarico, Silvia Caioli, Michela Murdocca, Annalucia Serafino, Marco Girasole, Simone Dinarelli, Giovanni Longo, Sabina Pucci, Annalisa Botta, Giuseppe Novelli, Cristina Zona, Ruggiero Mango, Federica Sangiuolo. Modelling the pathogenesis of Myotonic Dystrophy type 1 cardiac phenotype through human iPSC-derived cardiomyocytes. Journal of Molecular and Cellular Cardiology 2018; 118: 95 doi: 10.1016/j.yjmcc.2018.03.012
|
| 8 |
Patrick Connell, Tarah A. Word, Xander H. T. Wehrens. Targeting pathological leak of ryanodine receptors: preclinical progress and the potential impact on treatments for cardiac arrhythmias and heart failure. Expert Opinion on Therapeutic Targets 2020; 24(1): 25 doi: 10.1080/14728222.2020.1708326
|
| 9 |
Pei-Chi Yang, Wayne R. Giles, Luiz Belardinelli, Colleen E. Clancy. Mechanisms of flecainide induced negative inotropy: An in silico study. Journal of Molecular and Cellular Cardiology 2021; 158: 26 doi: 10.1016/j.yjmcc.2021.05.007
|
| 10 |
Kathy N. Wright. Small Animal Critical Care Medicine. 2023; : 961 doi: 10.1016/B978-0-323-76469-8.00177-5
|
| 11 |
Hasan Ashraf, Nway Ko Ko, Vatsal Ladia, Pradyumna Agasthi, Tadhg Prendiville, Fergus O’Herlihy, Sai Harika Pujari, Siva K. Mulpuru, Luis Scott, Dan Sorajja. Use of Flecainide in Stable Coronary Artery Disease: An Analysis of Its Safety in Both Nonobstructive and Obstructive Coronary Artery Disease. American Journal of Cardiovascular Drugs 2021; 21(5): 563 doi: 10.1007/s40256-021-00483-9
|
| 12 |
Alessandro Zorzi, Alberto Cipriani, Domenico Corrado. Anti-arrhythmic therapy in athletes. Pharmacological Research 2019; 144: 306 doi: 10.1016/j.phrs.2019.04.027
|
| 13 |
Rachel Lampert, Eugene H. Chung, Michael J. Ackerman, Alonso Rafael Arroyo, Douglas Darden, Rajat Deo, Joe Dolan, Susan P. Etheridge, Belinda R. Gray, Kimberly G. Harmon, Cynthia A. James, Jonathan H. Kim, Andrew D. Krahn, Andre La Gerche, Mark S. Link, Ciorsti MacIntyre, Lluis Mont, Jack C. Salerno, Maully J. Shah. 2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to play. Heart Rhythm 2024; 21(10): e151 doi: 10.1016/j.hrthm.2024.05.018
|
| 14 |
Fadhel A. Alomar, Chengju Tian, Sean R. Bidasee, Zachary L. Venn, Evan Schroder, Nicholas Y. Palermo, Mohammad AlShabeeb, Benson J. Edagwa, Jason J. Payne, Keshore R. Bidasee. HIV-Tat Exacerbates the Actions of Atazanavir, Efavirenz, and Ritonavir on Cardiac Ryanodine Receptor (RyR2). International Journal of Molecular Sciences 2022; 24(1): 274 doi: 10.3390/ijms24010274
|
| 15 |
Sevilay Goktas Sahoglu, Yusuf Enes Kazci, Erkan Tuncay, Tugce Torun, Celal Akdeniz, Volkan Tuzcu, Esra Cagavi. Functional evaluation of the tachycardia patient‐derived iPSC cardiomyocytes carrying a novel pathogenic SCN5A variant. Journal of Cellular Physiology 2022; 237(10): 3900 doi: 10.1002/jcp.30843
|
| 16 |
Enrico Paolini, Giulia Stronati, Federico Guerra, Alessandro Capucci. Flecainide: Electrophysiological properties, clinical indications, and practical aspects. Pharmacological Research 2019; 148: 104443 doi: 10.1016/j.phrs.2019.104443
|
| 17 |
Hector Martinez-Navarro, Xin Zhou, Alfonso Bueno-Orovio, Blanca Rodriguez. Electrophysiological and anatomical factors determine arrhythmic risk in acute myocardial ischaemia and its modulation by sodium current availability. Interface Focus 2021; 11(1): 20190124 doi: 10.1098/rsfs.2019.0124
|
| 18 |
Noah R Schneegurt, Christian Wright, Neil Glenn, Inderpal Thethi. Flecainide-Induced Acute Respiratory Distress Syndrome: A Case Report. Cureus 2024; doi: 10.7759/cureus.61637
|
| 19 |
Wayne A. Ray, Cecilia P. Chung, C. Michael Stein, Walter Smalley, Eli Zimmerman, William D. Dupont, Adriana M. Hung, James R. Daugherty, Alyson L. Dickson, Katherine T. Murray. Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation. Annals of Internal Medicine 2023; 176(6): 769 doi: 10.7326/M22-3238
|
| 20 |
Robert C. Klipp, Na Li, Qiongling Wang, Tarah A. Word, Martha Sibrian-Vazquez, Robert M. Strongin, Xander H.T. Wehrens, Jonathan J. Abramson. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2. Heart Rhythm 2018; 15(4): 578 doi: 10.1016/j.hrthm.2017.12.017
|
| 21 |
Justin Seltzer, Aaron Schneir. Case Files from the University of California San Diego Medical Toxicology Fellowship: Neonatal Flecainide Toxicity from an Accidental Dosing Error. Journal of Medical Toxicology 2024; 20(3): 314 doi: 10.1007/s13181-024-01018-9
|
| 22 |
Samuel Lévy. Cardioversion of recent‐onset atrial fibrillation using intravenous antiarrhythmics: A European perspective. Journal of Cardiovascular Electrophysiology 2021; 32(12): 3259 doi: 10.1111/jce.15264
|
| 23 |
Sukhjinder Chauhan, Desiree Morris, Mina Bhatnagar, Pinak Shah, Dhiraj D Narula. A Rare Case Report of Flecainide-Induced Left Bundle Branch Block (LBBB) and Transient Cardiomyopathy. Cureus 2023; doi: 10.7759/cureus.37184
|
| 24 |
Carlos E Guzmán, Carla Gabriela Guzmán-Moreno, José Luis Assad-Morell, Edgar Francisco Carrizales-Sepúlveda, Jalaj Garg, Christopher Wong, Markus Bettin, Stefan Simovic, Mariame Chakir. Flecainide toxicity associated with the use of goji berries: a case report. European Heart Journal - Case Reports 2021; 5(6) doi: 10.1093/ehjcr/ytab204
|
| 25 |
Tyson S. Burnham, Heidi T. May, Tami L. Bair, Jeffrey A. Anderson, Brian G. Crandall, Michael J. Cutler, John D. Day, Roger A. Freedman, Kirk U. Knowlton, Joseph B. Muhlestein, Leenhapong Navaravong, Ravi A. Ranjan, Benjamin A. Steinberg, T. Jared Bunch. Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease. American Heart Journal 2022; 243: 127 doi: 10.1016/j.ahj.2021.08.013
|
| 26 |
Hyung Ki Jeong, Sung Soo Kim, Hyun Kuk Kim, Young Jae Ki, Keun Ho Park, Dong Hyun Choi. A case of sinus arrest in atrial fibrillation with pulmonary embolism after flecainide ingestion. Translational and Clinical Pharmacology 2022; 30(4): 182 doi: 10.12793/tcp.2022.30.e19
|
| 27 |
Hannah Wilson, Declan Patton, Zena Moore, Tom O’Connor, Linda Nugent. Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy 2021; 7(5): 363 doi: 10.1093/ehjcvp/pvaa018
|
| 28 |
Juliia Belikova. THE RELATIONSHIP OF THE RATIO TAURINE/ALANINE IN SERUM AND INDICATORS OF HEART RATE VARIABILITY IN PATIENTS WITH POSTINFARCTION CARDIOSCLEROSIS AND DIABETES MELLITUS TYPE 2. The Ukrainian Scientific Medical Youth Journal 2019; 109(1): 6 doi: 10.32345/USMYJ.1(109).2019.6-10
|
| 29 |
Brett J. Wakefield, Anand R. Mehta. Transapical Ablation of Symptomatic Premature Ventricular Contractions in a Patient With Mechanical Mitral and Aortic Valves. Journal of Cardiothoracic and Vascular Anesthesia 2018; 32(6): 2700 doi: 10.1053/j.jvca.2017.12.043
|
| 30 |
Shenel A Khan, Soniya Emmanuel, Vivig Shantha Kumar, Resheek Nerella, Basim Shaman Ameen, Dev Patel, Jabez David John, Ranita Bodepudi, Saniya Seher, Sai Sri Penumetcha . Long QT Syndrome With Drugs Used in the Management of Arrhythmias: A Systematic Review. Cureus 2024; doi: 10.7759/cureus.65857
|
| 31 |
H. J. te Kolste, G. J. Kimman, T. Germans, S. A. J. Timmer. Between Scylla and Charybdis. Netherlands Heart Journal 2019; 27(7-8): 387 doi: 10.1007/s12471-019-1290-x
|
| 32 |
Deniz Eriş, Feyza Ayşenur Paç. Asymptomatic cardiac tumour with premature ventricular contraction in an athlete: case report. Cardiology in the Young 2022; 32(4): 644 doi: 10.1017/S1047951121003334
|
| 33 |
Satoru FUJII. Newly developed atrial fibrillation in the perioperative setting: what to do next?. Minerva Anestesiologica 2022; 88(6) doi: 10.23736/S0375-9393.22.16470-9
|
| 34 |
Krisztina Lévay, János Madarász, László Hegedűs. Tuning the chemoselectivity of the Pd-catalysed hydrogenation of pyridinecarbonitriles: an efficient and simple method for preparing pyridyl- or piperidylmethylamines. Catalysis Science & Technology 2022; 12(8): 2634 doi: 10.1039/D1CY02295D
|
| 35 |
EM Sutrisna. Personalized Medicine of flecainide (The Impact of the CYP2D6 and CYP1A2 Polymorphism on Responses to Flecainide). Biomedical and Pharmacology Journal 2024; 17(1): 15 doi: 10.13005/bpj/2830
|
| 36 |
Soroosh Kiani, Michael N. Sayegh, Rand Ibrahim, Neal K. Bhatia, Faisal M. Merchant, Anand D. Shah, Stacy B. Westerman, David B. De Lurgio, Anshul M. Patel, Christine M. Thompkins, Angel R. Leon, Michael S. Lloyd, Mikhael F. El-Chami. The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease. JACC: Clinical Electrophysiology 2023; 9(7): 1172 doi: 10.1016/j.jacep.2022.12.021
|
| 37 |
Lohit Garg, Manasvi Gupta, Syed Rafay Ali Sabzwari, Sahil Agrawal, Manyoo Agarwal, Talha Nazir, Jeffrey Gordon, Babak Bozorgnia, Matthew W. Martinez. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management. Heart Failure Reviews 2019; 24(2): 189 doi: 10.1007/s10741-018-9752-6
|
| 38 |
Athanasios Kartalis, Dimitrios Afendoulis, Petros Voutas, Maria Moutafi, Nikolaos Papagiannis, Stefanos Garoufalis, Nikolaos Kartalis, Nikolaos Smyrnioudis, Antonios Ziakas, Matthaios Didagelos. Acute Management of Paroxysmal Atrial Fibrillation with Intravenous Flecainide plus Oral Beta-Blockers. International Journal of Translational Medicine 2024; 4(2): 334 doi: 10.3390/ijtm4020021
|
| 39 |
Anton Stolear, Maxim Dulgher, Ju Young Bae, Lila Kaminsky, Gini P Jeyashanmugaraja, Uzodinma Emerenini. Wide Spectrum of Flecainide Toxicity: A Case Report and Literature Review. Cureus 2024; doi: 10.7759/cureus.62923
|
| 40 |
Manish Dwivedi, Sutanu Mukhopadhyay, Shalini Yadav, Kshatresh Dutta Dubey. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing. Computers in Biology and Medicine 2022; 146: 105607 doi: 10.1016/j.compbiomed.2022.105607
|
| 41 |
Pei-Chi Yang, Luiz Belardinelli, Colleen E. Clancy. Mechanisms of Chemical Atrial Defibrillation by Flecainide and Ibutilide. JACC: Clinical Electrophysiology 2024; doi: 10.1016/j.jacep.2024.08.009
|
| 42 |
C. Fielder Camm, A. John Camm. Pathy's Principles and Practice of Geriatric Medicine. 2022; : 360 doi: 10.1002/9781119484288.ch29
|
| 43 |
Vasudeva Reddy Netala, Sireesh Kumar Teertam, Huizhen Li, Zhijun Zhang. A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies. Cells 2024; 13(17): 1471 doi: 10.3390/cells13171471
|
| 44 |
K. D. Tiver, D. K. Martin, J. Quah, A. Lahiri, A. N. Ganesan. Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case report. Journal of Medical Case Reports 2023; 17(1) doi: 10.1186/s13256-023-03947-5
|
| 45 |
N.V. Bezditko. Lixarit — clinical and pharmaceutical aspects of efficacy and safety of flecainide acetate generic drug. HYPERTENSION 2022; 14(4): 21 doi: 10.22141/2224-1485.14.4.2021.240254
|
| 46 |
Harold Rivner, Litsa K. Lambrakos. Flecainide Toxicity Leading to Loss of Pacemaker Capture and Cardiac Arrest. JACC: Case Reports 2021; 3(4): 586 doi: 10.1016/j.jaccas.2020.11.030
|
| 47 |
Leah Acker, Kristen Bova Campbell, Colleen Naglee, Brad Taicher, Yuriy S. Bronshteyn. Perioperative Management of Flecainide: A Problem-Based Learning Discussion. A&A Practice 2021; 15(4): e01443 doi: 10.1213/XAA.0000000000001443
|
| 48 |
Patryk Klochowicz, Jacek W. Morzycki, Claudia M. Ramírez‐Lozano, Rosa Santillan, Dorota Czajkowska‐Szczykowska. Facile Synthesis of Hydroquinone Linked 3,3’‐Steroid Dimers via a Modified Mitsunobu Protocol. European Journal of Organic Chemistry 2024; 27(25) doi: 10.1002/ejoc.202400309
|
| 49 |
Francesco Moccia, Valentina Brunetti, Teresa Soda, Pawan Faris, Giorgia Scarpellino, Roberto Berra-Romani. Store-Operated Ca2+ Entry as a Putative Target of Flecainide for the Treatment of Arrhythmogenic Cardiomyopathy. Journal of Clinical Medicine 2023; 12(16): 5295 doi: 10.3390/jcm12165295
|
| 50 |
Muhammad Haris Ilyas, Amaan Mohammad Sharih, Jamila Tukur Jido, Abdul Rahman Zulfiqar Ali, Ava Khoshnaghsh, Mehak Nadeem, Syeda Anum Zahra. Screening for Atrial Fibrillation: Risks, Benefits, and Implications On Future Clinical Practice. Current Treatment Options in Cardiovascular Medicine 2024; 26(8): 233 doi: 10.1007/s11936-024-01047-1
|
| 51 |
Abdulrahman K Alraee, Tarique S Chachar, Ammar S Shaaban, Husam A Noor. Early Recognition and Management of Flecainide Toxicity: A Case Report and Literature Review. Cureus 2024; doi: 10.7759/cureus.73683
|
| 52 |
Jonathan W. Waks, Peter Zimetbaum. Antiarrhythmic Drug Therapy for Rhythm Control in Atrial Fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics 2017; 22(1): 3 doi: 10.1177/1074248416651722
|
| 53 |
Anders Einum, Philip von Brandis, Elisabeth Leirgul, Cathrine Ebbing. Monochorionic Twin Pregnancy Complicated by Arrhythmia in One Twin: Longitudinal Hemodynamic Effects of Flecainide Cardioversion Assessed by Fetal Venous Doppler. Journal of Fetal Medicine 2023; 10(03): 116 doi: 10.1055/s-0043-1774753
|
| 54 |
Fernando Wangüemert Pérez, Julio Salvador Hernández Afonso, María del Val Groba Marco, Eduardo Caballero Dorta, Luis Álvarez Acosta, Oscar Campuzano Larrea, Guillermo Pérez, Josep Brugada Terradellas, Ramón Brugada Terradellas. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia. Revista Española de Cardiología (English Edition) 2018; 71(3): 185 doi: 10.1016/j.rec.2017.04.032
|
| 55 |
Isabelle Malhamé, Christy Gandhi, Gofran Tarabulsi, Matthew Esposito, Kristin Lombardi, Antony Chu, Kenneth K Chen. Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia. Obstetric Medicine 2019; 12(2): 66 doi: 10.1177/1753495X18808118
|
| 56 |
Gheorghe-Andrei Dan, Dobromir Dobrev. Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging. IJC Heart & Vasculature 2018; 21: 11 doi: 10.1016/j.ijcha.2018.08.005
|
| 57 |
Pratik Khatiwada, Lindsey Clark, Arjun Khunger, Bhimesh B Rijal, Jody Ritter. A Case Report of Flecainide Toxicity With Review of Literature. Cureus 2022; doi: 10.7759/cureus.22261
|
| 58 |
James Boris, Hussein Al-Sudani, Aaron Brophy. Flecainide overdose-induced wide-complex tachyarrhythmia treated with sodium bicarbonate infusion. BMJ Case Reports 2024; 17(6): e256391 doi: 10.1136/bcr-2023-256391
|
| 59 |
Giampaolo Morciano, Alessandro Rimessi, Simone Patergnani, Veronica A.M. Vitto, Alberto Danese, Asrat Kahsay, Laura Palumbo, Massimo Bonora, Mariusz R. Wieckowski, Carlotta Giorgi, Paolo Pinton. Calcium dysregulation in heart diseases: Targeting calcium channels to achieve a correct calcium homeostasis. Pharmacological Research 2022; 177: 106119 doi: 10.1016/j.phrs.2022.106119
|
| 60 |
Chrysovalantou Nikolaidou, Konstantinos Kouskouras, Nikolaos Fragakis, Vassilios P. Vassilikos, Haralambos Karvounis, Theodoros D. Karamitsos. Bolus Intravenous Procainamide in Patients with Frequent Ventricular Ectopics during Cardiac Magnetic Resonance Scanning: A Way to Ensure High Quality Imaging. Diagnostics 2021; 11(2): 178 doi: 10.3390/diagnostics11020178
|
| 61 |
Jordi Cano, Esther Zorio, Andrea Mazzanti, Miguel Ángel Arnau, Beatriz Trenor, Silvia G. Priori, Javier Saiz, Lucia Romero. Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.580481
|
| 62 |
Dario Turturiello, Riccardo Cappato. The many NOs to the use of Class IC antiarrhythmics: weren’t the guidelines too strict?. European Heart Journal Supplements 2022; 24(Supplement_I): I47 doi: 10.1093/eurheartjsupp/suac073
|
| 63 |
Fernando Wangüemert Pérez, Julio Salvador Hernández Afonso, María del Val Groba Marco, Eduardo Caballero Dorta, Luis Álvarez Acosta, Oscar Campuzano Larrea, Guillermo Pérez, Josep Brugada Terradellas, Ramón Brugada Terradellas. La flecainida reduce las arritmias ventriculares en pacientes con taquicardia ventricular polimórfica catecolaminérgica genotipo RyR2 positivo. Revista Española de Cardiología 2018; 71(3): 185 doi: 10.1016/j.recesp.2017.04.014
|
| 64 |
Joachim R. Ehrlich, Christiane Look, Karel Kostev, Carsten W. Israel, Andreas Goette. Impact of dronedarone on the risk of myocardial infarction and stroke in atrial fibrillation patients followed in general practices in Germany. International Journal of Cardiology 2019; 278: 126 doi: 10.1016/j.ijcard.2018.11.133
|
| 65 |
Manuel Kraft, Antonius Büscher, Felix Wiedmann, Yannick L’hoste, Walter E. Haefeli, Norbert Frey, Hugo A. Katus, Constanze Schmidt. Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.638445
|
| 66 |
GD Singh. “C” Trouble: Class IC Anti-arrhythmic Toxicity. Journal of Cardiovascular Medicine and Cardiology 2017; : 033 doi: 10.17352/2455-2976.000047
|
| 67 |
Jennifer A. Ferrante, Muzammel Rizvi, Sami Sakaan, John Eick, B. Tate Cutshall. Consequences of AV blockade omission in flecainide therapy. The Nurse Practitioner 2021; 46(7): 10 doi: 10.1097/01.NPR.0000753872.27819.f7
|
| 68 |
Erind Gjermeni, Andreas Bollmann, Gerhard Hindricks, Andreas Müssigbrodt. Flecainide-Associated Cardiogenic Shock in a Patient with Atrial Fibrillation. Case Reports in Cardiology 2019; 2019: 1 doi: 10.1155/2019/4820652
|
| 69 |
Bao Hui Poh, Jan Hau Lee, Abdul Alim Abdul Haium, Tze Liang Jonathan Choo. Complete Heart Block Secondary to Flecainide Toxicity: Is It Time for CYP2D6 Genotype Testing?. Pediatrics 2020; 146(1) doi: 10.1542/peds.2019-2608
|